Seagen Inc.
seagen.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2023 10-Q, filed Nov 1, 2023. Its latest SEC filing is a 15-12G from Dec 26, 2023.
10-Q for Q3 FY2023, filed Nov 1, 2023
The sections below describe the company as of the FY2022 annual report.
What Did They Do?
Develops and commercializes targeted cancer medicines, including antibody-drug conjugates, for people with blood cancers and solid tumors.
10-K for FY2022, filed Feb 15, 2023Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. We are commercializing ADCETRIS®, or…View ↗
How Did They Make Money?
Seagen sells its medicines mainly through specialty distributors and pharmacies, and gets paid when they receive the products. It also receives sales-based royalties from partners and cash upfront or when development or sales milestones are met under technology licenses.
10-K for FY2022, filed Feb 15, 2023We sell our products primarily through a limited number of specialty distributors and specialty pharmacies in the U.S, and to a lesser…View ↗
Royalty revenues primarily reflect amounts earned under the ADCETRIS collaboration with Takeda Pharmaceutical Company Limited, or Takeda.…View ↗
We have collaboration and license agreements for our technology with a number of biotechnology and pharmaceutical companies. Under these…View ↗
$2B
-
10-K for FY2022, filed Feb 16, 2023
$2B ↗
Who Were Their Customers?
Seagen sells its products mainly through a limited number of specialty distributors and specialty pharmacies in the U.S., and to a lesser extent internationally.
10-K for FY2022, filed Feb 15, 2023
Did Revenues Turn Into Profits?
No. It lost $610.3M in FY2022.
10-K for FY2022, filed Feb 16, 2023
−$613MView ↗
10-K for FY2022, filed Feb 16, 2023
−$610.3MView ↗
10-K for FY2022, filed Feb 16, 2023
−$531.1MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q3 FY2023, filed Nov 1, 2023
−$215.8MView ↗
- ▲ +13% (Loss)
- vs −$190.8M in Q3 FY2022
-
Dec 14, 2023
Pfizer completed its acquisition of Seagen
Seagen became a wholly owned subsidiary of Pfizer, and its common shares ceased trading on Nasdaq.
Sources
8-K, filed Dec 14, 2023
As a result of the consummation of the transactions contemplated by the Merger Agreement, a change of control occurred and the Company…View ↗
Grew. Revenue grew 3.0x in 4 years, from $654.7M in FY2018 to $2B in FY2022, about 32% a year.
More medicines on the market
The older report described ADCETRIS and PADCEV as commercial products and tucatinib and tisotumab vedotin as pipeline candidates; the latest report also describes TUKYSA and TIVDAK as commercial medicines.
10-K for FY2019, filed Feb 6, 2020 10-K for FY2022, filed Feb 15, 2023Seattle Genetics is a biotechnology company that develops and commercializes therapies targeting cancer. We are commercializing ADCETRIS®…View ↗
The most advanced program in our clinical pipeline is tucatinib, an oral, small molecule tyrosine kinase inhibitor, or TKI, that is highly…View ↗
In collaboration with Genmab A/S, or Genmab, we are developing tisotumab vedotin, which is an ADC targeting tissue factor. We and Genmab…View ↗
Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. We are commercializing ADCETRIS®, or…View ↗
Who Did They Compete With?
Competes with Bristol-Myers Squibb, Merck, Acrotech Biopharma, Kyowa Kirin, Janssen, Daiichi Sankyo, AstraZeneca, MacroGenics, Byondis, Agenus, Iovance Biotherapeutics, Regeneron Pharmaceuticals, Sanofi, and Roche
10-K for FY2022, filed Feb 15, 2023With respect to ADCETRIS, there are several other FDA approved drugs for its approved indications. Bristol-Myers Squibb's, or BMS's…View ↗
Loading...
